Microsoft partners pharma major Novartis for drug development
Microsoft has joined hands with Novartis to explore how to take advantage of advanced Artificial Intelligence (AI) technology. The partnership […]
Say something
Microsoft has joined hands with Novartis to explore how to take advantage of advanced Artificial Intelligence (AI) technology. The partnership […]
In an attempt to expand its portfolio of eye care medicines, Swiss drugmaker Novartis AG has acquired Takeda Pharmaceutical Company […]
Moody’s Investors Service has revised to negative from stable the outlook on the Aa3 long-term ratings of Novartis AG (Novartis) […]
Pharma giant Pfizer is alleged cutting down its work force in India by insisting they retire voluntarily. The company has […]
Researchers have discovered a promising new malaria drug with the potential to treat resistant strains of the deadly disease in a single dose, according to a study published recently in the journal Science.
Novartis announces the introduction of Triaminic Fever Reducer Pain Reliever, the only branded over-the-counter children’s liquid acetaminophen product currently available nationwide in the US.
In conversation with Divya Chawla from eHEALTH, Ashit Panjwani, utive Director – Marketing, Sales & Alliances, SAS Institute (India) Pvt Ltd, shares insights into the business of health and life sciences vertical of SAS.
Rural health facilities in Tanzania have successfully used mobile and electronic mapping technology to track and manage the delivery and stock levels of antimalarial drugs and ensure that treatments are available to malaria patients, where and when required.
Through its local organizations in countries throughout the region, Novartis is providing the equivalent of over USD 2.5 million in immediate emergency aid for victims of the recent earthquake in Haiti.
CREMA – Clinical Research Education and Management Academy, is a premier training and research institute in Clinical and Biomedical studies. Launched in 2007 in Mumbai, it runs three campuses at Bengaluru, New Delhi and Hyderabad and plans to set up three more centers by the end of 2009. Last year CREMA started a full-time Advanced Post Graduate Ddiploma in Clinical Research.
India and other developing countries are set to lobby hard for funding mechanisms to develop medicines,
mostly aimed at neglected diseases such as tuberculosis and malaria, at a forum set up by the World Health Organization or WHO. Developed countries have long maintained that patents are sufficient incentive for innovation.
It has come to the notice that despite the presence of a patent law that guards against giving exclusive commercial rights for modifications of existing medicines, research firms, both multinational and domestic, have tried their luck on 80 patent applications on TB drugs pending with Indian patent offices across the country.